HIV post-treatment controllers have distinct immunological and virological features.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
14 03 2023
Historique:
entrez: 6 3 2023
pubmed: 7 3 2023
medline: 9 3 2023
Statut: ppublish

Résumé

HIV post-treatment controllers (PTCs) are rare individuals who maintain low levels of viremia after stopping antiretroviral therapy (ART). Understanding the mechanisms of HIV post-treatment control will inform development of strategies aiming at achieving HIV functional cure. In this study, we evaluated 22 PTCs from 8 AIDS Clinical Trials Group (ACTG) analytical treatment interruption (ATI) studies who maintained viral loads ≤400 copies/mL for ≥24 wk. There were no significant differences in demographics or frequency of protective and susceptible human leukocyte antigen (HLA) alleles between PTCs and post-treatment noncontrollers (NCs, n = 37). Unlike NCs, PTCs demonstrated a stable HIV reservoir measured by cell-associated RNA (CA-RNA) and intact proviral DNA assay (IPDA) during analytical treatment interruption (ATI). Immunologically, PTCs demonstrated significantly lower CD4

Identifiants

pubmed: 36877848
doi: 10.1073/pnas.2218960120
pmc: PMC10089217
doi:

Substances chimiques

RNA 63231-63-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2218960120

Subventions

Organisme : NIAID NIH HHS
ID : UM1 AI069501
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069412
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069534
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI164560
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI068636
Pays : United States
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007387
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069423
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI045008
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069412
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068634
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150396
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106701
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI068634
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068636
Pays : United States

Références

J Acquir Immune Defic Syndr. 2006 Jun;42(2):140-8
pubmed: 16760795
Pathog Immun. 2016 Spring;1(1):154-164
pubmed: 27668293
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
N Engl J Med. 2006 Nov 30;355(22):2283-96
pubmed: 17135583
J Exp Med. 2007 Nov 26;204(12):3027-36
pubmed: 18025129
Antivir Ther. 2015;20(8):855-63
pubmed: 25906138
Nature. 2019 Feb;566(7742):120-125
pubmed: 30700913
JAMA. 2012 Jul 25;308(4):379-86
pubmed: 22820791
Antimicrob Agents Chemother. 2009 Apr;53(4):1532-8
pubmed: 19188387
Vaccine. 2009 Oct 9;27(43):6088-94
pubmed: 19450647
PLoS Pathog. 2021 Nov 18;17(11):e1010090
pubmed: 34793581
PLoS Genet. 2014 Mar 06;10(3):e1004196
pubmed: 24603468
Sci Transl Med. 2012 Feb 29;4(123):123ra25
pubmed: 22378925
Adv Immunol. 2013;119:51-83
pubmed: 23886064
Antivir Ther. 2012;17(6):1001-9
pubmed: 22865544
N Engl J Med. 2009 Feb 12;360(7):692-8
pubmed: 19213682
J Virol. 2023 Jan 31;97(1):e0125422
pubmed: 36541802
J Infect Dis. 2008 Jan 1;197(1):126-33
pubmed: 18171295
J Infect Dis. 2007 May 15;195(10):1426-36
pubmed: 17436222
J Virol. 2011 Oct;85(19):10189-200
pubmed: 21813616
BMC Bioinformatics. 2011 Jun 22;12:253
pubmed: 21693065
J Infect Dis. 2015 Jun 1;211(11):1726-34
pubmed: 25489001
AIDS. 2012 Nov 28;26(18):2409-12
pubmed: 23032411
Nature. 2002 May 2;417(6884):95-8
pubmed: 11986671
Arch Intern Med. 2012 Sep 10;172(16):1252-5
pubmed: 22826124
AIDS. 2022 Jan 1;36(1):95-105
pubmed: 34581306
Clin Infect Dis. 2020 Apr 10;70(8):1636-1642
pubmed: 31131858
AIDS. 2015 Sep 24;29(15):2003-7
pubmed: 26355572
J Infect Dis. 2018 Nov 5;218(12):1954-1963
pubmed: 30085241
J Immunol. 2013 Jul 15;191(2):540-4
pubmed: 23772031
J Infect Dis. 2011 Oct 15;204(8):1227-36
pubmed: 21917896
Nat Immunol. 2021 Aug;22(8):1020-1029
pubmed: 34312547
PLoS Pathog. 2014 May 15;10(5):e1004078
pubmed: 24831517
J Infect Dis. 2021 Feb 15;223(12 Suppl 2):4-12
pubmed: 33586773
AIDS. 2011 Jun 1;25(9):1207-17
pubmed: 21505304
AIDS. 2009 Sep 24;23(15):1987-95
pubmed: 19696651
PLoS One. 2010 May 10;5(5):e10555
pubmed: 20479938
Science. 2019 May 3;364(6439):480-484
pubmed: 31048489
Immunity. 2021 Oct 12;54(10):2372-2384.e7
pubmed: 34496223
Open Forum Infect Dis. 2015 Jan 13;2(1):ofu117
pubmed: 25884005
J Immunol. 2009 Nov 15;183(10):6612-8
pubmed: 19846870
Sci Transl Med. 2021 Dec 15;13(624):eabl4097
pubmed: 34910552
AIDS. 2016 Jan 28;30(3):343-53
pubmed: 26588174
mBio. 2021 Dec 21;12(6):e0307821
pubmed: 34844430
J Infect Dis. 2020 Oct 13;222(10):1655-1659
pubmed: 32443148
J Infect Dis. 2010 Sep 1;202(5):705-16
pubmed: 20662716
Nat Commun. 2022 Jan 10;13(1):121
pubmed: 35013215
Cell. 2013 Oct 24;155(3):540-51
pubmed: 24243014
PLoS Pathog. 2013 Mar;9(3):e1003211
pubmed: 23516360
J Infect Dis. 2006 Dec 15;194(12):1672-6
pubmed: 17109338
Sci Transl Med. 2020 Jan 29;12(528):
pubmed: 31996465
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11970-5
pubmed: 23818644
BMC Res Notes. 2011 Oct 20;4:427
pubmed: 22011438
Antimicrob Agents Chemother. 2012 Mar;56(3):1427-33
pubmed: 22183172
J Infect Dis. 2011 Jul 1;204(1):154-63
pubmed: 21628670
J Infect Dis. 2006 Sep 1;194(5):623-32
pubmed: 16897661
Cell. 2022 Jan 20;185(2):266-282.e15
pubmed: 35026153
AIDS. 2011 Sep 24;25(15):1823-32
pubmed: 21572306
PLoS One. 2014 May 06;9(5):e95524
pubmed: 24802242
AIDS. 2000 May 26;14(8):F77-82
pubmed: 10853971
J Infect Dis. 2022 Feb 15;225(4):675-685
pubmed: 34448873
Nat Protoc. 2008;3(7):1240-8
pubmed: 18600229
PLoS One. 2012;7(2):e30881
pubmed: 22363505
Pathog Immun. 2017;2(3):431-445
pubmed: 29333522
Elife. 2014 Sep 12;3:e03821
pubmed: 25217531
Blood. 2006 Jun 15;107(12):4781-9
pubmed: 16467198
J Infect Dis. 2013 Jun 1;207(11):1694-702
pubmed: 23460751
Nature. 2020 Sep;585(7824):261-267
pubmed: 32848246
Front Immunol. 2022 Jan 27;13:803417
pubmed: 35154118
J Infect Dis. 2017 Mar 15;215(6):911-919
pubmed: 28453847
J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):153-60
pubmed: 25072610
mBio. 2021 Mar 9;12(2):
pubmed: 33688003
Nat Med. 2021 Nov;27(11):1893-1898
pubmed: 34711975
Clin Infect Dis. 2022 Mar 9;74(5):865-870
pubmed: 34117753
PLoS Pathog. 2021 Aug 27;17(8):e1009825
pubmed: 34449812
J Infect Dis. 2013 Jul;208(1):50-6
pubmed: 23089590
J Infect Dis. 2013 Aug 15;208(4):662-71
pubmed: 23687222

Auteurs

Behzad Etemad (B)

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139.

Xiaoming Sun (X)

Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139.

Yijia Li (Y)

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139.

Meghan Melberg (M)

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139.

Daniela Moisi (D)

School of Medicine, Case Western Reserve University, Cleveland, OH 44106.

Rachel Gottlieb (R)

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139.

Hayat Ahmed (H)

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139.

Evgenia Aga (E)

Harvard T. H. Chan School of Public Health, Boston, MA 02115.

Ronald J Bosch (RJ)

Harvard T. H. Chan School of Public Health, Boston, MA 02115.

Edward P Acosta (EP)

School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233.

Yuko Yuki (Y)

Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702.
Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20814.

Maureen P Martin (MP)

Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702.
Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20814.

Mary Carrington (M)

Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139.
Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702.
Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20814.

Rajesh T Gandhi (RT)

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.

Jeffrey M Jacobson (JM)

School of Medicine, Case Western Reserve University, Cleveland, OH 44106.

Paul Volberding (P)

School of Medicine, University of California San Francisco, San Francisco, CA 94143.

Elizabeth Connick (E)

Department of Medicine, University of Arizona, Tucson, AZ 85724.

Ronald Mitsuyasu (R)

School of Medicine, University of California Los Angeles, Los Angeles, CA 90095.

Ian Frank (I)

School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.

Michael Saag (M)

School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233.

Joseph J Eron (JJ)

Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.

Daniel Skiest (D)

Department of Medicine, University of Massachusetts Chan Medical School - Baystate, Springfield, MA 01199.

David M Margolis (DM)

Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.

Diane Havlir (D)

School of Medicine, University of California San Francisco, San Francisco, CA 94143.

Robert T Schooley (RT)

Department of Medicine, University of California San Diego, San Diego, CA 92103.

Michael M Lederman (MM)

School of Medicine, Case Western Reserve University, Cleveland, OH 44106.

Xu G Yu (XG)

Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139.

Jonathan Z Li (JZ)

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH